Terence Friedlander, MD

Terence Friedlander, MD

Chief of Hematology-Oncology at Zuckerberg San Francisco General; Associate Director for Cancer Research at ZSFG, Helen Diller Family Comprehensive Cancer Center; Associate Clinical Professor, Division of Hematology/Oncology, UCSF

Cancer Center Program Membership

Molecular Oncology

Phone: (415) 476-4616 (appts)

Box 3211, UCSF
San Francisco, CA 94143-3211

Physician Biography

UCSF Profiles

Research Summary

I am a clinical and translational oncologist specializing in cancers of the genitourinary tract, specifically bladder and prostate cancers. I also lead the Division of Hematology and Oncology at Zuckerberg San Francisco General Hospital and Trauma Center. My research is focused on understanding the basic biology of urologic malignancies and in developing novel therapeutic ways to treat disease. As a clinical academic oncologist I serve as principal investigator or co-investigator on a number clinical trials in advanced cancers including studies of immunotherapy, novel targeted therapy, and genetically guided therapy. All of our studies rely on strong collaboration between investigators spanning from the bench to the bedside to advance our understanding of how to best treat cancers for all our patients.

Education

Brown University, BA, 5/99
New York University School of Medicine, 2003, MD
UCSF Medical Center, 2003-2006, Residency
Utrecht University, Netherlands, 2007, Medical Ethics
UCSF Medical Center, 2007-2010, Oncology Fellowship

Honors & Awards

  • 2006
    Fullbright Scholarship in Medical Ethics, Netherlands-America Foundation
  • 2010
    ASCO Young Investigator Award, American Society of Clinical Oncology
  • 2011
    ASCO Merit Award, American Society of Clinical Oncology
  • 2012
    Physician Research Training Aaward, United States Department of Defense
  • 2012
    Young Investigator Award, Prostate Cancer Foundation
  • 2012
    Young Investigator Travel Award, Advances in Circulating Tumor Cells Symposium
  • 2019
    UCSF Division of Hematology and Oncology Teaching Award

Selected Publications

  1. Chen E, Cario CL, Leong L, Lopez K, Márquez CP, Chu C, Li PS, Oropeza E, Tenggara I, Cowan J, Simko JP, Chan JM, Friedlander T, Wyatt AW, Aggarwal R, Paris PL, Carroll PR, Feng F, Witte JS Cell-free DNA concentration and fragment size as a biomarker for prostate cancer.  View on PubMed
  2. Balcerek J, Trejo E, Levine K, Couey P, Kornberg ZV, Rogine C, Young C, Li PJ, Shy BR, Taylor JE, Bakhtary S, Friedlander T, Lynch KL, Bern C, Esensten JH Hospital-Based Donor Recruitment and Predonation Serologic Testing for COVID-19 Convalescent Plasma.  View on PubMed
  3. Amara D, Wisel SA, Braun HJ, Collisson EA, Friedlander T, Worner G, Roll GR, Hirose R, Stock PG Metastatic Donor-derived Malignancies Following Simultaneous Pancreas-kidney Transplant: Three Case Reports and Management Strategies.  View on PubMed
  4. Atreya CE, Collisson EA, Park M, Grenert JP, Behr SC, Gonzalez A, Chou J, Maisel S, Friedlander TW, Freise CE, Shoji J, Semrad TJ, Van Ziffle J, Chin-Hong P Molecular Insights in Transmission of Cancer From an Organ Donor to Four Transplant Recipients.  View on PubMed
  5. Ott PA, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N, Margolin K, Awad MM, Hellmann MD, Lin JJ, Friedlander T, Bushway ME, Balogh KN, Sciuto TE, Kohler V, Turnbull SJ, Besada R, Curran RR, Trapp B, Scherer J, Poran A, Harjanto D, Barthelme D, Ting YS, Dong JZ, Ware Y, Huang Y, Huang Z, Wanamaker A, Cleary LD, Moles MA, Manson K, Greshock J, Khondker ZS, Fritsch E, Rooney MS, DeMario M, Gaynor RB, Srinivasan L A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer.  View on PubMed
  6. Kwon DH, Friedlander TW Does One Size Fit All? Re-evaluating Prostate-specific Antigen Progression Thresholds for Clinical Trials.  View on PubMed
  7. Cario CL, Chen E, Leong L, Emami NC, Lopez K, Tenggara I, Simko JP, Friedlander TW, Li PS, Paris PL, Carroll PR, Witte JS A machine learning approach to optimizing cell-free DNA sequencing panels: with an application to prostate cancer.  View on PubMed
  8. Oh DY, Kwek SS, Raju SS, Li T, McCarthy E, Chow E, Aran D, Ilano A, Pai CS, Rancan C, Allaire K, Burra A, Sun Y, Spitzer MH, Mangul S, Porten S, Meng MV, Friedlander TW, Ye CJ, Fong L Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer.  View on PubMed
  9. Posadas EM, Chi KN, de Wit R, de Jonge MJA, Attard G, Friedlander TW, Yu MK, Hellemans P, Chien C, Abrams C, Jiao JJ, Saad F Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study.  View on PubMed
  10. Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chang S, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Guzzo T, Herr HW, Hoffman-Censits J, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wright JL, Gurski LA, Johnson-Chilla A Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.  View on PubMed
  11. Zuniga KB, Borno H, Chan JM, Van Blarigan EL, Friedlander TW, Wang S, Zhang L, Kenfield SA The Problem of Underrepresentation: Black Participants in Lifestyle Trials Among Patients with Prostate Cancer.  View on PubMed
  12. Kwon DH, Friedlander T A TITAN step forward: apalutamide for metastatic castration-sensitive prostate cancer.  View on PubMed
  13. O'Donnell PH, Arkenau HT, Sridhar SS, Ong M, Drakaki A, Spira AI, Zhang J, Gordon MS, Degboe AN, Gupta AK, Mukhopadhyay P, Huang W, Abdullah SE, Angra N, Roskos LK, Guo X, Friedlander T Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose-escalation study 1108.  View on PubMed
  14. Friedlander TW, Welty C, Anantharaman A, Schonhoft JD, Jendrisak A, Lee J, Li P, Hough J, Stromlund A, Edwards M, Sangar S, Kobayashi Y, Simko J, Farrokhian N, Lindquist K, Greene S, Ontiveros P, Graf R, Rodriquez A, Suraneni M, Wang Y, Landers M, Carroll P, Cooperberg MR, Dittamore R, Paris PL Identification and Characterization of Circulating Tumor Cells in Men Who have Undergone Prostatectomy for Clinically Localized, High Risk Prostate Cancer.  View on PubMed
  15. Grivas P, Drakaki A, Friedlander TW, Sonpavde G Conceptual Framework for Therapeutic Development Beyond Anti-PD-1/PD-L1 in Urothelial Cancer.  View on PubMed
  16. Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.  View on PubMed
  17. Lee M, Hong H, Kim W, Zhang L, Friedlander TW, Fong L, Lin AM, Small EJ, Wei XX, Rodvelt TJ, Miralda B, Stocksdale B, Ryan CJ, Aggarwal R Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 Study.  View on PubMed
  18. Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak DP, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wile G, Johnson-Chilla A, Dwyer MA, Gurski LA NCCN Guidelines Insights: Bladder Cancer, Version 5.2018.  View on PubMed
  19. Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.  View on PubMed
  20. Almassi N, Reichard C, Li J, Russell C, Perry J, Ryan CJ, Friedlander T, Sharifi N HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer.  View on PubMed

Go to UCSF Profiles, powered by CTSI